Calidi Biotherapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
CLDI$0.68-6.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| (Unaudited) | ||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(5,062) | $(7,225) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 91 | 102 |
| Amortization of right of use assets | 303 | 272 |
| Amortization of debt discount and financing costs | — | 16 |
| Stock-based compensation | 607 | 888 |
| Change in fair value of other liabilities and derivatives | (35) | 199 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (317) | 1,575 |
| Accounts payable | (752) | 968 |
| Accrued expenses and other current liabilities | (1,687) | (388) |
| Operating lease right of use liability | (279) | (238) |
| Net cash used in operating activities | (7,131) | (3,831) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of machinery and equipment | (7) | (5) |
| Net cash used in investing activities | (7) | (5) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from Public Offerings | 6,573 | — |
| Proceeds from Registered Direct Offering | 3,503 | — |
| Repayment of principal on related party term notes payable | (1,250) | — |
| Repayment of principal on term notes payable | (200) | — |
| Repayment of principal on related party bridge loan payable | (200) | — |
| Repayment of financing lease obligations | (17) | (23) |
| Proceeds from issuance of convertible notes payable | — | 3,000 |
| Related party proceeds from issuance of loan payable | — | 200 |
| Payment of interest on loan payable | — | (2) |
| Payment of financing costs | (301) | (162) |
| Net cash provided by financing activities | 8,108 | 3,013 |
| Effect of exchange rate changes on cash | — | 17 |
| NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH | 970 | (806) |
| CASH AND RESTRICTED CASH BALANCE: | ||
| At beginning of the period | 9,809 | 2,167 |
| At end of the period | $10,779 | $1,361 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||
| Cash paid for interest | $639 | $24 |
| Cash paid for income taxes | $3 | $2 |
| SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES | ||
| Financing fees | $80 | $248 |
| Issuance of common stock in lieu of cash for services | $— | $29 |
| Issuance of common stock in lieu of cash for SEPA commitment fee | $— | $81 |
| Issuance of warrants for legal settlement | $— | $158 |
| Issuance of convertible note for legal settlement | $— | $1,500 |
| Discount on convertible note payable | $— | $149 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.